IDEC 10603--IDEC Y2B8 ADMINISTERED TO PATIENTS WITH B CELL LYMPHOMA
IDEC 10603--IDEC Y2B8 ADMINISTERED TO PATIENTS WITH B CELL LYMPHOMA
批准号:
6114067
负责人:
Leo I. Gordon
金额:
$2.05万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-12-01 至 1999-11-30
中文摘要
IDEC-Y2B8(IDEC-103)是一种小鼠IgG1 kappa单抗,IDEC-C2B8(IDEC-102)是一种嵌合的IgG1 kappa单抗,具有鼠可变区和人恒定区。这两种抗体都识别表达在正常B细胞和大多数恶性B细胞淋巴瘤上的CD20抗原,并显示出特异性。在食蟹猴身上进行的大剂量安全性研究表明,这两种抗体都没有不良临床事件,实验室测试或组织病理学也没有显著异常。体外作用机制研究表明,IDEC-C2B8能结合人补体并裂解淋巴B细胞系。此外,它在抗体依赖的细胞毒性检测中具有显著的活性。正如预测的那样,这些抗体的生物学效应表现为外周血、淋巴结和骨髓中的B细胞耗尽。在单独的研究中,7次q.o.d后几周。IDEC-2B8剂量组和IDEC-C2B8每周4次剂量组小鼠骨髓中B细胞明显减少。外周血中B细胞的恢复(至基线的75%)通常分别发生在最后一剂IDEC-2B8和IDEC-C2B8后的38天和60天内。
英文摘要
IDEC-Y2B8 (IDEC-103) is a murine IgG1 kappa monoclonal antibody and IDEC-C2B8 (IDEC-102) is a chimeric igG1 kappa monoclonal antibody, with mouse variable and human constant regions. Both antibodies recognize and show specificity for the CD20 antigen expressed on normal B cells and most malignant B-cell lymphomas. High-dose safety studies in cynomolgus monkeys have revealed no adverse clinical events with either antibody, and there were no significant abnormalities on laboratory tests or on histopathology. In vitro mechanism of action studies have demonstrated that IDEC-C2B8 binds human complement and lyses lymphoid B-cell lines. Additionally, it has significant activity in assays for antibody-dependent cellular cytotoxicity. As predicted, the biologic effect of these antibodies is manifested by B-cell depletion in peripheral blood, lymph nodes and bone marrow. In separate studies, several weeks after seven q.o.d. doses of IDEC-2B8, and three weeks after four weekly doses of IDEC-C2B8, a significant decrease of B cells in bone marrow was observed. Recovery of the B cells in the peripheral blood (to >75% of baseline) usually occurred within 38 days and 60 days following the last dose of IDEC-2B8 and IDEC-C2B8, respectively.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IDEC Y2B8 RADIOIMMUNOTHERAPY COMPARED TO RITUXAN IN RELAPSED B CELL LYMPHOMA
-
批准号:6304166
-
项目类别:
-
资助金额:$2.05万
-
财政年份:1999
-
负责人:Leo I. Gordon
-
依托单位:
IDEC Y2B8 RADIOIMMUNOTHERAPY IN B CELL NON HODGKINS LYMPHOMA
-
批准号:6304157
-
项目类别:
-
资助金额:$2.05万
-
财政年份:1999
-
负责人:Leo I. Gordon
-
依托单位:
IDEC Y2B8 RADIOIMMUNOTHERAPY FOR NON HODGKINS LYMPHOMA AFTER RITUXIMAB
-
批准号:6304161
-
项目类别:
-
资助金额:$2.05万
-
财政年份:1999
-
负责人:Leo I. Gordon
-
依托单位:
MODULATION OF POST BMT LUNG INJURY BY CAPTOPRIL
-
批准号:2551560
-
项目类别:
-
资助金额:$7.4万
-
财政年份:1998
-
负责人:Leo I. Gordon
-
依托单位:
IDEC Y2B8 RADIOIMMUNOTHERAPY FOR NON HODGKINS LYMPHOMA AFTER RITUXIMAB
-
批准号:6263971
-
项目类别:
-
资助金额:$2.05万
-
财政年份:1998
-
负责人:Leo I. Gordon
-
依托单位:
IDEC Y2B8 RADIOIMMUNOTHERAPY IN B CELL NON HODGKINS LYMPHOMA
-
批准号:6263967
-
项目类别:
-
资助金额:$2.05万
-
财政年份:1998
-
负责人:Leo I. Gordon
-
依托单位:
IDEC Y2B8 RADIOIMMUNOTHERAPY COMPARED TO RITUXAN IN RELAPSED B CELL LYMPHOMA
-
批准号:6263976
-
项目类别:
-
资助金额:$2.05万
-
财政年份:1998
-
负责人:Leo I. Gordon
-
依托单位:
MODULATION OF POST BMT LUNG INJURY BY CAPTOPRIL
-
批准号:2896367
-
项目类别:
-
资助金额:$7.4万
-
财政年份:1998
-
负责人:Leo I. Gordon
-
依托单位:
IDEC 106-03--PHASE I/II CLINICAL TRIAL TO EVALUATE IDEC-Y2B8
-
批准号:6245190
-
项目类别:
-
资助金额:$1.2万
-
财政年份:1997
-
负责人:Leo I. Gordon
-
依托单位:
IDEC 10603--IDEC Y2B8 ADMINISTERED TO PATIENTS WITH B CELL LYMPHOMA
-
批准号:6275302
-
项目类别:
-
资助金额:$2.26万
-
财政年份:1997
-
负责人:Leo I. Gordon
-
依托单位:
AIDS RELATED LYMPHOMAS--CLINICAL AND BIOLOGIC STUDIES
-
批准号:3200001
-
项目类别:
-
资助金额:$29.48万
-
财政年份:1991
-
负责人:Leo I. Gordon
-
依托单位:
AIDS RELATED LYMPHOMAS--CLINICAL AND BIOLOGIC STUDIES
-
批准号:3200000
-
项目类别:
-
资助金额:$35.92万
-
财政年份:1991
-
负责人:Leo I. Gordon
-
依托单位:
AIDS RELATED LYMPHOMAS--CLINICAL AND BIOLOGIC STUDIES
-
批准号:2096660
-
项目类别:
-
资助金额:$30.4万
-
财政年份:1991
-
负责人:Leo I. Gordon
-
依托单位:
IDEC 10603--IDEC Y2B8 ADMINISTERED TO PATIENTS WITH B CELL LYMPHOMA
-
批准号:6304182
-
项目类别:
-
资助金额:$2.05万
-
财政年份:--
-
负责人:Leo I. Gordon
-
依托单位:
海外基金